CLINICAL TRIALS PROFILE FOR PEMIGATINIB
✉ Email this page to a colleague
All Clinical Trials for PEMIGATINIB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02393248 ↗ | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Recruiting | Incyte Corporation | Phase 1/Phase 2 | 2015-02-27 | The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3). |
| NCT02872714 ↗ | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | Active, not recruiting | Incyte Corporation | Phase 2 | 2017-01-12 | The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations. |
| NCT02924376 ↗ | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | Completed | Incyte Corporation | Phase 2 | 2017-01-16 | The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment. |
| NCT03011372 ↗ | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | Recruiting | Incyte Corporation | Phase 2 | 2017-04-25 | The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement. |
| NCT03235570 ↗ | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) | Completed | Incyte Corporation | Phase 1 | 2017-08-01 | The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies. |
| NCT03498521 ↗ | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | Recruiting | Foundation Medicine, Inc. | Phase 2 | 2018-07-10 | This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PEMIGATINIB
Condition Name
Clinical Trial Locations for PEMIGATINIB
Trials by Country
Clinical Trial Progress for PEMIGATINIB
Clinical Trial Phase
Clinical Trial Sponsors for PEMIGATINIB
Sponsor Name
